Patient Dosing Begins in VIITAL Study of EB-101, a Treatment for Recessive Dystrophic Epidermolysis Bullosa

The first patient has been dosed in the third phase of the VIITAL study, which is intended to evaluate the effectiveness of EB-101. This medication is a gene-corrected cell therapy…

Continue Reading Patient Dosing Begins in VIITAL Study of EB-101, a Treatment for Recessive Dystrophic Epidermolysis Bullosa
Partnership Will Allow The Development of New Drug For Dystrophic Epidermolysis Bullosa
rawpixel / Pixabay

Partnership Will Allow The Development of New Drug For Dystrophic Epidermolysis Bullosa

According to a story from pm360online.com, the drug development company ProQR Therapeutics N.V. will be partnering with EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF) in order to…

Continue Reading Partnership Will Allow The Development of New Drug For Dystrophic Epidermolysis Bullosa